Immuron (IMRN) Gross Margin (2016 - 2024)
Immuron (IMRN) posted quarterly Gross Margin of 21833218650105.83% for Q4 2024, down 2183321865017292.2% year-over-year from N/an in Q1 2024, and down 32543397522554.72% quarter-over-quarter from 67.09% in Q4 2023.
Immuron (IMRN) Gross Margin (2016 - 2024) Analysis & Trends
Immuron's Gross Margin history runs 9 years deep, the most recent figure standing at 21833218650105.83% for Q4 2024.
- In Q4 2024, Gross Margin fell 2183321865017292.2% year-over-year to 21833218650105.83%; the TTM figure through Dec 2024 stood at 15824138666020.42% (down 1582413866602055.0% YoY), while the FY2025 annual figure was 65.39%, down 267.0% from the prior year.
- Gross Margin for Q4 2024 stood at 21833218650105.83%, down from 67.09% in the prior quarter.
- The five-year high for Gross Margin was 38529715.89% in Q4 2020, with the low at 21833218650105.83% in Q4 2024.
- The 5-year median for Gross Margin is 70.2% (2023), against an average of 3638863353361.13%.
- The sharpest annual moves came in 2020 and 2024: Gross Margin jumped 2000000000 bps in 2020, then sank 2000000000 bps in 2024.
- Immuron's Gross Margin stood at 38529715.89% in 2020, then tumbled by 100 bps to 0.0% in 2021, then jumped by 104824652 bps to 73.32% in 2022, then decreased by 8 bps to 67.09% in 2023, then slumped by 2000000000 bps to 21833218650105.83% in 2024.
- Business Quant data shows IMRN's Gross Margin at 21833218650105.83% in Q4 2024, 67.09% in Q4 2023, and 82.75% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -21,833,218,650,105.83% |
| Dec 31, 2023 | 67.09% |
| Jun 30, 2023 | 82.75% |
| Dec 31, 2022 | 73.32% |
| Dec 31, 2021 | 0.00% |
| Dec 31, 2020 | 38,529,715.89% |
| Dec 31, 2019 | 72.04% |
| Dec 31, 2018 | 76.34% |
| Dec 31, 2017 | 78.75% |
| Dec 31, 2016 | 68.23% |
| Jun 30, 2016 | 73.91% |